Skip to main content

ResearchHubLoading navigation…

Loading ResearchHub…

Immunotherapy | ResearchHub - ResearchHub

Explore the network

Research, people, journals and institutions — all in one place.

Explore

01Research 02Smart search 03Researchers 04Journals 05Institutions 06RHR Rankings 07ResearchHub platform 08Events

Work together

Turn ideas into projects, questions and reusable datasets.

Connect

01Projects 02Questions 03Datasets

Stay informed

Follow trends, opportunities and your research library.

Insights

01Research trends 02Opportunities 03Library 04Research services 05ResearchHub Pro 06Pricing

ResearchHub

Explore ResearchHub.

Personal

01Recommended research 02Research intelligence

Home Search Network Library Log in

ResearchHub

Research, connected

Explore the graph

X

Download ResearchHub

GET IT ONGoogle PlayComing soonDownload on theApp StoreComing soonEXPLORE IT ONAppGalleryComing soon

Research

Research Researchers Journals Institutions RHR Rankings

Contribute

Projects Questions Datasets Opportunities

Platform

ResearchHub platform About Blog Community Help API Licensing

Shopping

Contact and support

Need help, have a question, or want to contact the ResearchHub team?

Contact and support support@aresearch.uk

© 2026 ResearchHub. Built for responsible scholarly connection.

Privacy Terms Cookies This work is licensed under Creative Commons Attribution 4.0 InternationalCC BY 4.0

Privacy-aware community infrastructure

Journal graph

Immunotherapy

Informa UK Limited · ISSN 1750-743X

3

Verified works

0

Citations

—

Access

Researchers publishing here

7 linked researchers

Lisheng Huang Huide Zhu Ling Fang Xiaohan Hu Amin Haiderali Yezhou Sun Wilbur Pan

Research in this journal

Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma2026 · Lisheng Huang, Huide Zhu, Ling Fang · 0 citations

Real-world utilization of immune checkpoint inhibitors in medicare-eligible patients with triple-negative breast cancer in the United States2026 · Xiaohan Hu, Amin Haiderali, Yezhou Sun · 0 citations

Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer2026 · Calogera Claudia Spagnolo, Irene Campo, Elena Fassi · 0 citations